ArticleFrontiers in medicine2025
Cell death-related signature genes: risk-predictive biomarkers and potential therapeutic targets in severe sepsis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a systemic inflammatory response syndrome that predisposes to severe lung infections (SeALAR) such as sepsis-associated acute lung injury (Se/ALI) or sepsis-associated acute respiratory distress syndrome (Se/ARDS). Through a systematic bioinformatics approach, this study aimed to unravel the pathogenesis of SeALAR and explore potential biomarkers and individualized therapeutic targets. We analyzed differential genes in the peripheral blood of SeALAR patients based on the GSE10474 and GSE32707 datasets, and identified 352 significantly differentially expressed genes. Various signaling pathways related to immune regulation were found to be significantly altered via GO and KEGG enrichment analysis. Further combining cell death-related gene screening and four machine learning algorithms (including LASSO-logistic, Gradient Boosting Machine, Random Forest and xGBoost), nine SeALAR-characterized cell death genes (SeDGs) were screened and a risk prediction model based on SeDGs was constructed that demonstrated good prediction performance. In immunoassays, ssGSEA showed that Activated.CD8.T.cell, CD56bright.natural.killer.cell, MDSC, Natural.killer.T.cell, T.follicular.helper. cell and TType.1.T.helper.cell had significantly lower infiltration abundance than lower infiltration levels compared to the Se group. GSEA analysis revealed key immune pathways in which SeDGs may be involved. In addition, unsupervised clustering analysis revealed that SeALAR patients could be classified into two molecular subtypes, providing a new direction for the development of individualized immunotherapy strategies. In conclusion, this study systematically analyzed the molecular features and immune disorder mechanism of SeALAR from a multidimensional perspective, and thus provides a theoretical basis and potential targets for precision medicine intervention and targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.